Employees: 2,776
Size Sirio Pharma (300791.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $759M, the 2701st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.50 on 18 Nov 2026.
Performance Over six months the shares fell 6.1%, against -19.1% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue fell 9.2% over the last twelve months (peer median +0.5%); the operating margin is 1.2% (peer median 9.5%).
Valuation It trades at 16.2× forward earnings against a peer median of 20.7× (5th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.5 points below its cost of capital (7.3% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.04B | CN¥4.25B | CN¥4.20B | CN¥3.57B | CN¥2.50B |
| Revenue growth | — | +1% | +17% | +43% | — |
| Gross profit | CN¥1.46B | CN¥1.22B | CN¥1.25B | CN¥1.01B | CN¥732M |
| EBITDA | n/a | CN¥540M | CN¥689M | CN¥581M | CN¥379M |
| Net income | CN¥106M | CN¥137M | CN¥325M | CN¥281M | CN¥212M |
| Free cash flow | CN¥101M | CN¥130M | CN¥159M | -CN¥63.4M | CN¥175M |
| Capital expenditure | CN¥372M | CN¥441M | CN¥412M | CN¥452M | CN¥294M |
| Total debt | CN¥2.04B | CN¥1.71B | CN¥1.62B | CN¥1.39B | CN¥937M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300791.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.4% | -9.2% | 10th lowest of 21 |
| 6-month return | -6.1% | -19.1% | 5th highest of 21 |
| Distance from 52-week high | -37.0% | -40.9% | 9th highest of 21 |
| Revenue growth (TTM) | -9.2% | +0.5% | 7th lowest of 20 |
| Operating margin | 1.2% | 9.5% | 5th lowest of 21 |
| Forward P/E | 16.2× | 20.7× | 5th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | 14.1% | 4.7% | 6th most demanding of 14 |
| Growth delivered (Del g) | +15.6% | +12.1% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -1.4 pp | -7.3 pp | 5th most demanding of 14 |
| ROIC minus cost of capital | -2.5 pp | +0.4 pp | 7th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 16.2× | 14.1% | +15.6% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | 7.6× | n/a | n/a |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | n/a | 2.1% | -1.3% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $703M | -20% | -14% | 22% | n/a | 0.4% | +4.8% |
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 47.7× | 24.3% | +13.4% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 8.7× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $668M | -33% | +8% | 4% | n/a | 4.0% | +13.5% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $641M | -22% | -28% | -25% | n/a | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 33.5× | 4.7% | +18.5% |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $613M | -30% | 0% | 0% | n/a | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 182.0× | n/a | n/a |
| ABA Chemicals 300261.SZ | China | $592M | -26% | -16% | -23% | 405.0× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 21.4× | 24.6% | +38.5% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $583M | -23% | +21% | 11% | 45.4× | 19.1% | +12.1% |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.01B | -17% | -5% | 4% | 20.0× | 0.5% | +7.9% |
| ArriVent BioPharma AVBP | United States | $564M | -60% | n/a | -3,620% | n/a | n/a | n/a |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $548M | -9% | +6% | 6% | n/a | 15.4% | +6.5% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $532M | -2% | -4% | 21% | n/a | 1.4% | +7.0% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |